top of page

ATS2024: Endeavor BioMedicines' Hedgehog inhibitor showed improvements in lung function, capacity, and other measures at 12-weeks in IPF

  • blonca9
  • May 20, 2024
  • 1 min read

John Hood describes how the 12 week data Endeavor is witnessing is giving the company optimism that it might be reversing, rather than slowing down, the progression of this difficult to treat disease.



Join the BiotechTV mailing list

Thanks for subscribing!

Follow BiotechTV

  • Twitter
  • LinkedIn
  • Facebook
  • TikTok
  • Instagram

Also look for unique social pages for BiotechTV U.

Sponsor Spotlight

evaluate-logo-png_seeklogo-457165-2_edited.png

Evaluate is a trusted provider of forecasting and commercial intelligence to the pharmaceutical industry. With a combination of gold standard data sources and deep pharma expertise, Evaluate helps clients make the right portfolio decisions to drive growth.

Evaluate's solutions provide a complete, dynamic view of development risk and commercial return across the full clinical lifecycle, underpinned by consensus forecasts to 2032, pipelines, deals and more. A consulting and analytics team is on always hand to help clients address unique clinical and commercial challenges.

bottom of page